Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

736 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reovirus-based therapy for cancer.
Kelly K, Nawrocki S, Mita A, Coffey M, Giles FJ, Mita M. Kelly K, et al. Among authors: coffey m. Expert Opin Biol Ther. 2009 Jul;9(7):817-30. doi: 10.1517/14712590903002039. Expert Opin Biol Ther. 2009. PMID: 19527106 Review.
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S, Goel S. Gollamudi R, et al. Among authors: coffey m. Invest New Drugs. 2010 Oct;28(5):641-9. doi: 10.1007/s10637-009-9279-8. Epub 2009 Jul 2. Invest New Drugs. 2010. PMID: 19572105 Free PMC article. Clinical Trial.
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS. Comins C, et al. Among authors: coffey mc. Clin Cancer Res. 2010 Nov 15;16(22):5564-72. doi: 10.1158/1078-0432.CCR-10-1233. Epub 2010 Oct 6. Clin Cancer Res. 2010. PMID: 20926400 Free PMC article. Clinical Trial.
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K. Galanis E, et al. Among authors: coffey m. Mol Ther. 2012 Oct;20(10):1998-2003. doi: 10.1038/mt.2012.146. Epub 2012 Aug 7. Mol Ther. 2012. PMID: 22871663 Free PMC article. Clinical Trial.
Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production.
Chakrabarty R, Tran H, Fortin Y, Yu Z, Shen SH, Kolman J, Onions D, Voyer R, Hagerman A, Serl S, Kamen A, Thompson B, Coffey M. Chakrabarty R, et al. Among authors: coffey m. Appl Microbiol Biotechnol. 2014 Feb;98(4):1763-70. doi: 10.1007/s00253-013-5499-0. Epub 2014 Jan 14. Appl Microbiol Biotechnol. 2014. PMID: 24419798
The oncolytic virus, pelareorep, as a novel anticancer agent: a review.
Chakrabarty R, Tran H, Selvaggi G, Hagerman A, Thompson B, Coffey M. Chakrabarty R, et al. Among authors: coffey m. Invest New Drugs. 2015 Jun;33(3):761-74. doi: 10.1007/s10637-015-0216-8. Epub 2015 Feb 19. Invest New Drugs. 2015. PMID: 25693885 Review.
736 results